New Risk • May 07
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 2.8% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (2.8% operating cash flow to total debt). High level of non-cash earnings (21% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (2.9% net profit margin). Reported Earnings • Apr 25
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥0.59 (up from CN¥0.57 in FY 2024). Revenue: CN¥15.9b (down 8.3% from FY 2024). Net income: CN¥978.9m (up 3.8% from FY 2024). Profit margin: 6.2% (up from 5.4% in FY 2024). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 7.1%. Earnings per share (EPS) also missed analyst estimates by 20%. Revenue is forecast to grow 8.0% p.a. on average during the next 2 years, compared to a 7.7% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Price Target Changed • Apr 08
Price target increased by 17% to CN¥11.76 Up from CN¥10.09, the current price target is provided by 1 analyst. New target price is 65% above last closing price of CN¥7.12. Stock is up 11% over the past year. The company is forecast to post earnings per share of CN¥0.74 for next year compared to CN¥0.57 last year. Announcement • Mar 30
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong to Report Q1, 2026 Results on Apr 30, 2026 Star Lake Bioscience Co., Inc.Zhaoqing Guangdong announced that they will report Q1, 2026 results on Apr 30, 2026 Announcement • Dec 26
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong to Report Fiscal Year 2025 Results on Mar 17, 2026 Star Lake Bioscience Co., Inc.Zhaoqing Guangdong announced that they will report fiscal year 2025 results on Mar 17, 2026 Reported Earnings • Oct 29
Third quarter 2025 earnings released: EPS: CN¥0.11 (vs CN¥0.10 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.11 (up from CN¥0.10 in 3Q 2024). Revenue: CN¥3.92b (down 9.0% from 3Q 2024). Net income: CN¥178.8m (up 4.6% from 3Q 2024). Profit margin: 4.6% (up from 4.0% in 3Q 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • Sep 30
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong to Report Q3, 2025 Results on Oct 31, 2025 Star Lake Bioscience Co., Inc.Zhaoqing Guangdong announced that they will report Q3, 2025 results on Oct 31, 2025 Price Target Changed • Jul 11
Price target increased by 8.6% to CN¥9.51 Up from CN¥8.76, the current price target is an average from 3 analysts. New target price is 26% above last closing price of CN¥7.52. Stock is up 29% over the past year. The company is forecast to post earnings per share of CN¥0.81 for next year compared to CN¥0.57 last year. Announcement • Jun 30
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong to Report First Half, 2025 Results on Aug 28, 2025 Star Lake Bioscience Co., Inc.Zhaoqing Guangdong announced that they will report first half, 2025 results on Aug 28, 2025 Declared Dividend • Jun 22
Dividend of CN¥0.38 announced Dividend of CN¥0.38 is the same as last year. Ex-date: 23rd June 2025 Payment date: 23rd June 2025 Dividend yield will be 5.2%, which is higher than the industry average of 2.2%. Sustainability & Growth Dividend is covered by both earnings (54% earnings payout ratio) and cash flows (30% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. EPS is expected to grow by 34% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • May 15
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong, Annual General Meeting, Jun 06, 2025 Star Lake Bioscience Co., Inc.Zhaoqing Guangdong, Annual General Meeting, Jun 06, 2025, at 10:00 China Standard Time. Location: The Company's Meeting Room, Zhaoqing, Guangdong China Price Target Changed • May 13
Price target increased by 7.5% to CN¥8.84 Up from CN¥8.22, the current price target is an average from 3 analysts. New target price is 20% above last closing price of CN¥7.37. Stock is down 6.1% over the past year. The company is forecast to post earnings per share of CN¥0.79 for next year compared to CN¥0.57 last year. Major Estimate Revision • Apr 28
Consensus EPS estimates increase by 11%, revenue downgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from CN¥18.8b to CN¥18.1b. EPS estimate rose from CN¥0.717 to CN¥0.795. Net income forecast to grow 15% next year vs 25% growth forecast for Food industry in China. Consensus price target up from CN¥8.22 to CN¥8.76. Share price rose 4.6% to CN¥7.50 over the past week. New Risk • Apr 23
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company. Announcement • Mar 28
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong to Report Q1, 2025 Results on Apr 22, 2025 Star Lake Bioscience Co., Inc.Zhaoqing Guangdong announced that they will report Q1, 2025 results on Apr 22, 2025 Announcement • Dec 27
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong to Report Fiscal Year 2024 Results on Apr 22, 2025 Star Lake Bioscience Co., Inc.Zhaoqing Guangdong announced that they will report fiscal year 2024 results on Apr 22, 2025 Reported Earnings • Oct 30
Third quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.16 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.10 (down from CN¥0.16 in 3Q 2023). Revenue: CN¥4.30b (down 3.6% from 3Q 2023). Net income: CN¥171.1m (down 34% from 3Q 2023). Profit margin: 4.0% (down from 5.8% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Price Target Changed • Oct 29
Price target increased by 11% to CN¥8.22 Up from CN¥7.43, the current price target is an average from 2 analysts. New target price is 28% above last closing price of CN¥6.43. Stock is up 21% over the past year. The company is forecast to post earnings per share of CN¥0.61 for next year compared to CN¥0.41 last year. Valuation Update With 7 Day Price Move • Oct 28
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥7.09, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 17x in the Food industry in China. Total returns to shareholders of 79% over the past three years. Announcement • Sep 30
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong to Report Q3, 2024 Results on Oct 29, 2024 Star Lake Bioscience Co., Inc.Zhaoqing Guangdong announced that they will report Q3, 2024 results on Oct 29, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥5.71, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 16x in the Food industry in China. Total returns to shareholders of 48% over the past three years. Buy Or Sell Opportunity • Jul 23
Now 20% undervalued The stock has been flat over the last 90 days, currently trading at CN¥5.18. The fair value is estimated to be CN¥6.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 59% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 6.3% in 2 years. Earnings are forecast to grow by 60% in the next 2 years. Announcement • Jun 28
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong to Report First Half, 2024 Results on Aug 27, 2024 Star Lake Bioscience Co., Inc.Zhaoqing Guangdong announced that they will report first half, 2024 results on Aug 27, 2024 New Risk • May 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (41% net debt to equity). Short dividend paying track record (less than a year of continuous dividend payments). Share price has been volatile over the past 3 months (8.8% average weekly change). Buy Or Sell Opportunity • May 09
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 97% to CN¥7.99. The fair value is estimated to be CN¥6.51, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 59% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 9.1% in 2 years. Earnings are forecast to grow by 55% in the next 2 years. Valuation Update With 7 Day Price Move • May 08
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to CN¥7.26, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 21x in the Food industry in China. Total returns to shareholders of 85% over the past three years. New Risk • Apr 28
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 41% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (41% net debt to equity). Short dividend paying track record (less than a year of continuous dividend payments). Reported Earnings • Apr 24
First quarter 2024 earnings released: EPS: CN¥0.15 (vs CN¥0.073 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.15 (up from CN¥0.073 in 1Q 2023). Revenue: CN¥4.20b (flat on 1Q 2023). Net income: CN¥251.5m (up 109% from 1Q 2023). Profit margin: 6.0% (up from 2.9% in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Announcement • Apr 23
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong, Annual General Meeting, May 13, 2024 Star Lake Bioscience Co., Inc.Zhaoqing Guangdong, Annual General Meeting, May 13, 2024, at 10:00 China Standard Time. Location: The Company's Meeting Room, Zhaoqing, Guangdong China Valuation Update With 7 Day Price Move • Apr 23
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to CN¥4.79, the stock trades at a trailing P/E ratio of 13.3x. Average trailing P/E is 27x in the Food industry in China. Total returns to shareholders of 22% over the past three years. Buy Or Sell Opportunity • Apr 10
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 7.1% to CN¥4.33. The fair value is estimated to be CN¥5.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 82% over the last 3 years. Earnings per share has grown by 33%. Announcement • Mar 30
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong to Report Q1, 2024 Results on Apr 23, 2024 Star Lake Bioscience Co., Inc.Zhaoqing Guangdong announced that they will report Q1, 2024 results on Apr 23, 2024 Buy Or Sell Opportunity • Mar 25
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 6.1% to CN¥4.30. The fair value is estimated to be CN¥5.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 82% over the last 3 years. Earnings per share has grown by 33%. Buy Or Sell Opportunity • Feb 28
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 20% to CN¥4.15. The fair value is estimated to be CN¥5.38, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 82% over the last 3 years. Earnings per share has grown by 33%. Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to CN¥3.53, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 26x in the Food industry in China. Total loss to shareholders of 7.6% over the past three years. Buy Or Sell Opportunity • Feb 02
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 29% to CN¥3.83. The fair value is estimated to be CN¥4.96, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 82% over the last 3 years. Earnings per share has grown by 33%. Announcement • Dec 29
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong to Report Fiscal Year 2023 Results on Apr 23, 2024 Star Lake Bioscience Co., Inc.Zhaoqing Guangdong announced that they will report fiscal year 2023 results on Apr 23, 2024 Reported Earnings • Nov 04
Third quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.053 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.16 (up from CN¥0.053 in 3Q 2022). Revenue: CN¥4.46b (up CN¥4.11b from 3Q 2022). Net income: CN¥259.2m (up CN¥220.4m from 3Q 2022). Profit margin: 5.8% (down from 11% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. New Risk • Aug 30
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.8% Last year net profit margin: 4.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (125% increase in shares outstanding). Minor Risk Profit margins are more than 30% lower than last year (2.8% net profit margin). Announcement • Jun 28
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong to Report First Half, 2023 Results on Aug 29, 2023 Star Lake Bioscience Co., Inc.Zhaoqing Guangdong announced that they will report first half, 2023 results on Aug 29, 2023 Reported Earnings • Mar 29
Full year 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.14 in FY 2021) Full year 2022 results: EPS: CN¥0.51 (up from CN¥0.14 in FY 2021). Revenue: CN¥17.5b (up CN¥16.3b from FY 2021). Net income: CN¥608.3m (up 471% from FY 2021). Profit margin: 3.5% (down from 8.6% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Yan Wang was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 25
Third quarter 2022 earnings released: EPS: CN¥0.053 (vs CN¥0.005 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.053 (up from CN¥0.005 in 3Q 2021). Revenue: CN¥352.0m (up 44% from 3Q 2021). Net income: CN¥38.8m (up CN¥35.2m from 3Q 2021). Profit margin: 11% (up from 1.5% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Reported Earnings • Aug 14
Second quarter 2022 earnings released: EPS: CN¥0.075 (vs CN¥0.056 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.075 (up from CN¥0.056 in 2Q 2021). Revenue: CN¥353.1m (up 28% from 2Q 2021). Net income: CN¥55.5m (up 34% from 2Q 2021). Profit margin: 16% (in line with 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Aug 11
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥6.68, the stock trades at a trailing P/E ratio of 52.1x. Average trailing P/E is 40x in the Food industry in China. Total returns to shareholders of 40% over the past three years. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. 3 independent directors (7 non-independent directors). Independent Director Yan Wang was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Mar 30
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: CN¥0.14 (down from CN¥0.20 in FY 2020). Revenue: CN¥1.24b (up 11% from FY 2020). Net income: CN¥106.5m (down 28% from FY 2020). Profit margin: 8.6% (down from 13% in FY 2020). Revenue missed analyst estimates by 3.8%. Earnings per share (EPS) also missed analyst estimates by 12%. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Mar 28
Investor sentiment improved over the past week After last week's 25% share price gain to CN¥8.00, the stock trades at a trailing P/E ratio of 49.9x. Average trailing P/E is 39x in the Food industry in China. Total returns to shareholders of 43% over the past three years. Board Change • Mar 22
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. 3 independent directors (7 non-independent directors). Independent Director Yan Wang was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Dec 28
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥5.73, the stock trades at a trailing P/E ratio of 35.7x. Average trailing P/E is 41x in the Food industry in China. Total returns to shareholders of 81% over the past three years. Announcement • Dec 05
FSPG Hi-Tech CO., Ltd. (SZSE:000973), Guangdong Xingfa Aluminium Co., Ltd. and Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (SHSE:600866) entered into an agreement to acquire 10% stake in Guangdong Guangxin Innovative Research Centre Co. from Guangdong Guangxin Holdings Group Ltd. for CNY 33.5 million. FSPG Hi-Tech CO., Ltd. (SZSE:000973), Guangdong Xingfa Aluminium Co., Ltd. and Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (SHSE:600866) entered into an agreement to acquire 10% stake in Guangdong Guangxin Innovative Research Centre Co. from Guangdong Guangxin Holdings Group Ltd. for CNY 33.5 million on December 3, 2021. Pursuant to the agreement, Guangdong Xingfa's consideration amounts to CNY 11.2 million. The audited consolidated total asset value and net asset value of the Guangdong Guangxin and its subsidiary were approximately CNY 335 million and approximately CNY 327 million, respectively, as at 31 July 2021. Reported Earnings • Oct 26
Third quarter 2021 earnings released: EPS CN¥0.005 (vs CN¥0.035 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥243.8m (up 10% from 3Q 2020). Net income: CN¥3.57m (down 86% from 3Q 2020). Profit margin: 1.5% (down from 12% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 24
Second quarter 2021 earnings released: EPS CN¥0.056 (vs CN¥0.07 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥277.0m (down 7.2% from 2Q 2020). Net income: CN¥41.4m (down 19% from 2Q 2020). Profit margin: 15% (down from 17% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 28
First quarter 2021 earnings released: EPS CN¥0.047 (vs CN¥0.044 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: CN¥304.0m (up 6.0% from 1Q 2020). Net income: CN¥34.6m (up 7.4% from 1Q 2020). Profit margin: 11% (in line with 1Q 2020). Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Feb 04
New 90-day low: CN¥3.77 The company is down 18% from its price of CN¥4.57 on 06 November 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Food industry, which is up 20% over the same period. Is New 90 Day High Low • Jan 15
New 90-day low: CN¥4.39 The company is down 7.0% from its price of CN¥4.73 on 16 October 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Food industry, which is up 16% over the same period. Is New 90 Day High Low • Dec 23
New 90-day high: CN¥4.95 The company is up 5.0% from its price of CN¥4.72 on 24 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Food industry, which is up 1.0% over the same period. Is New 90 Day High Low • Oct 30
New 90-day low: CN¥4.42 The company is down 9.0% from its price of CN¥4.87 on 31 July 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Food industry, which is down 4.0% over the same period. Reported Earnings • Oct 29
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥137.5m, up 3.8% from the prior year. Total revenue was CN¥1.01b over the last 12 months, down 4.7% from the prior year. Announcement • Oct 20
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong to Report Q3, 2020 Results on Oct 27, 2020 Star Lake Bioscience Co., Inc.Zhaoqing Guangdong announced that they will report Q3, 2020 results on Oct 27, 2020 Announcement • Jul 09
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong to Report First Half, 2020 Results on Aug 25, 2020 Star Lake Bioscience Co., Inc.Zhaoqing Guangdong announced that they will report first half, 2020 results on Aug 25, 2020 
